News & Information | START In The News

Welcome to START’s News & Information page.  Here you'll find the latest news releases and articles about START. Take a moment to browse through some of the stories that have been written about START.

December 1st, 2014

Legendary Spur, Tim Duncan, donates $247,000 to fund ground-breaking San Antonio cancer genome research project

The San Antonio 1000 Cancer Genome Project may forever change the way we think about and treat cancer
September 23rd, 2014

Skin Cancer Breakthrough: New melanoma Treatment

New 4 San Antonio
Breakthrough in melanoma treatment
September 8th, 2014

New treatment for advanced skin cancer was tested in S.A.

KENS 5
By: KENS 5
September 4th, 2014

FDA approves drug that was first tested by SA-based START

A breakthrough for patients with advanced melanoma, Pembrolizumab, will now be a part of standard-of-care for patients with advanced melanoma
April 10th, 2014

Investigative CDK Inhibitor Shows Promise in Breast Cancer

Medscape
By: Roxanne Nelson
"Hormone receptor positivity is currently the best available biomarker to select patients with breast cancer most likely to benefit from treatment," Dr. Patnaik suggested. "LY2835219 warrants further investigation in larger, confirmatory clinical trials for women with breast cancer," she said.
April 9th, 2014

Bemaciclib Seems Safe, Effective for Advanced Disease

Breastcancer.org Discussion Boards
By: Gregory D. Pawelski
"This is a novel oral treatment for patients with metastatic breast cancer," said lead researcher Dr. Amita Patnaik, the associate director of clinical research at South Texas Accelerated Research Therapeutics in San Antonio.
April 9th, 2014

CDK4/6 Inhibitor LY2835219 Shows Promise in Early Study

OncLive
By: OncLive Silas Inman
"Although our study was not designed to compare patient outcomes based on HR status, the clinical benefit rate was 61% in our patients with HR-positive breast cancer, which means patients had disease control for longer than 24 weeks or had their tumors reduce in size by more than 30%," said the study's lead author Amita Patnaik, MD, an associate director of clinical research at South Texas Accelerated Research Therapeutics in San Antonio, Texas. - See more at: http://www.onclive.com/conference-coverage/aacr-2014/Lilly-CDK46-Inhibitor-Shows-Promise-in-Early-Study#sthash.ntOnkH5a.dpuf
April 7th, 2014

Experimental Breast Cancer Drug Seems Safe, Effective for Advanced Disease

U.S. News and World Reports
SUNDAY, April 6, 2014 (HealthDay News) -- In an early trial, an experimental breast cancer drug stopped disease growth and shrank tumors by more than 30 percent in some patients.
April 7th, 2014

San Antonio Developed Cancer Drug Unveiled for Metastatic Breast Cancer

WOAI 1200
By: Jim Forsyth
Groundbreaking research conducted by San Antonio's START Center is all the buzz at the annual American Association for Cancer Research convention in San Diego, 1200 WOAI news reports.
April 7th, 2014

Lilly CDK4/6 Inhibitor Shows Promise in Early Study

OncLive
By: Silas Inman
The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with hormone receptor (HR)-positive metastatic breast cancer, according to a phase I expansion cohort analysis presented at the 2014 AACR Annual Meeting.
April 4th, 2014

Cancer drug trial showing promise on how certain cancers are treated

KSAT
By: Kirsten Schaffer, Producer
Findings to be released at American Association of Cancer Research annual meeting this weekend
January 19th, 2014

Dr. Drew Rasco named as a San Antonio Business Journal Rising Star

San Antonio Business Journal
Dr. Drew W. Rasco, clinical investigator for START has been named one of the San Antonio Business Journal's 40 Under 40 recipients.
January 9th, 2014

Cancer Decline Seen a Result of Lifestyle Changes

1200 WOAI
By: Jim Forsyth

'The Big C' is in a big decline, and local ongologist and cancer researcher Dr. Drew Rasco with San Antonio's START Center for Cancer Care says you have only yourself to credit.